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Abstract
Background: Human Immunodeficiency Virus (HIV) is a global threat to public health. Current
therapies that directly target the virus often are rendered ineffective due to the emergence of drug-
resistant viral variants. An emerging concept to combat drug resistance is the idea of targeting host
mechanisms that are essential for the propagation of the virus, but have a minimal cellular effect.
Results: Herein, using Random Homozygous Gene Perturbation (RHGP), we have identified
cellular targets that allow human MT4 cells to survive otherwise lethal infection by a wild type HIV-
1NL4-3. These gene targets were validated by the reversibility of the RHGP technology, which
confirmed that the RHGP itself was responsible for the resistance to HIV-1 infection. We further
confirmed by siRNA knockdowns that the RHGP-identified cellular pathways are responsible for
resistance to infection by either CXCR4 or CCR5 tropic HIV-1 variants. We also demonstrated
that cell clones with these gene targets disrupted by RHGP were not permissible to the replication
of a drug resistant HIV-1 mutant.
Conclusion: These studies demonstrate the power of RHGP to identify novel host targets that
are essential for the viral life cycle but which can be safely perturbed without overt cytotoxicity.
These findings suggest opportunities for the future development of host-oriented therapeutics with
the broad spectrum potential for safe and effective inhibition of HIV infection.
Background
Therapy-resistant HIV-1 strains are relentlessly emerging
as a result of the error-prone HIV viral reverse tran-
scriptase, robust viral replication and incomplete patient
compliance. In some regions, viruses that are resistant to
drug cocktail therapy or HAART (Highly Active Antiretro-
viral Therapy) were isolated from nearly 20% of AIDS
patients evaluated [1,2]. Such findings increase the
Published: 29 September 2009
Virology Journal 2009, 6:154 doi:10.1186/1743-422X-6-154
Received: 10 July 2009
Accepted: 29 September 2009
This article is available from: http://www.virologyj.com/content/6/1/154
© 2009 Mao et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Virology Journal 2009, 6:154 http://www.virologyj.com/content/6/1/154
Page 2 of 14
(page number not for citation purposes)
urgency to identify new paradigms for the treatment of
HIV/AIDS, especially mechanisms of action that are rela-
tively insensitive to the development of resistance.
It is well established that interplay between the viruses
and host cells determines the outcome of viral pathogen-
esis, ranging from the elimination of viruses to latent or
lethal infections. HIV-1 is known to interact with host cel-
lular proteins to aid their replication and evade immune
attack. One example involves individuals who carry a
defective cell surface receptor (CCR5) and have been
shown to be resistant to HIV-1 infection [3,4]. Similar
interactions have been reported to encompass nearly
every step of HIV-1 life cycle: from viral entry [5] to viral
budding and release [6]. Such findings suggest that
increased understanding of the interaction of HIV-1 with
host protein could improve therapeutic and prevention
strategies to combat HIV/AIDS.
In light of the understood importance of host factors in
HIV-1 infection, increasing investigation has begun to
consider host targets for antiviral therapy. Specifically,
host targets that are essential for HIV-1 replication, but
not for the host cell itself, could provide a new modality
of treatment. It is further postulated that certain host tar-
gets might not place direct selective pressure on the path-
ogen and thus minimize the acquisition of drug
resistance. Host-directed therapeutics has begun to be suc-
cessfully deployed against HIV/AIDS, including treat-
ments that target the CD4 viral receptor and associated co-
receptors [7,8]. Indeed, some of the newest approved and
most promising experimental therapeutic options include
small molecules or biologics that target these host pro-
teins.
Not all host molecules are suitable as therapeutic targets
as many serve essential functions for the growth, function
or survival of host cells. However, it is increasingly under-
stood that viruses often circumvent the expression or
function of some host proteins (in a process known as
"hijacking") and this may provide an opportunity to tar-
get host molecules that are inappropriately expressed or
functionally altered in HIV-infected cells. To identify such
targets, our laboratory has employed a novel technology,
Random Homozygous Gene Perturbation (RHGP), to
select for targets that are essential for HIV infection but
which are not necessary for the growth, survival or func-
tion of non-infected cells. RHGP was designed to allow
the investigator to up- or down-regulate any gene in a
eukaryotic cell, independent of any prior knowledge or
annotation of that gene [9]. In this manner, RHGP pro-
vides an un-biased approach to identify any target,
whether up- or down-regulated, which is responsible for a
desired phenotype. As one example, our laboratory has
successfully used RHGP to identify and validate target
genes that allow host cells to survive an otherwise lethal
infection with Influenza A virus[10]. Of 110 targets iden-
tified by this genome wide screen technology, most (106
of 110) had not been described previously or linked with
influenza infection. In addition, we ascribed novel func-
tions to previously unknown genes and orfs (open read-
ing frames).
Herein, we apply RHGP and identify a set of host-oriented
targets that allow host cells to resist lethal HIV infection.
These novel targets include both known genes and non-
annotated ESTs (Expression Sequence Tags), whose func-
tions have not been assigned. We validated these genes
using unique properties of the RHGP technology as well
as independent genetic targeting approaches such as
siRNA. This investigation provides increased understand-
ing of the interplay between host targets and HIV and
could provide potential therapeutic targets to combat
HIV/AIDS.
Methods
Cell lines and Viruses
The following cell lines, viruses and proviral molecular
clones were obtained through the AIDS Research and Ref-
erence Reagent Program, Division of AIDS, NIAID, NIH:
MT4 cells from Dr. Douglas Richman, PM1 cells from Dr.
Marvin Reitz [11], TZM-bl cells from Dr. John C. Kappes,
Dr. Xiaoyun Wu and Tranzyme Inc. [12], pNL4-3 from Dr.
Malcolm Martin[13], HIV-1ME1 from Dr. Phalguni Gupta
[14] and Protease-resistant HIV-1 (L10R/M46I/L63P/
V82T/I84V) from Dr. Emilio Emini[15]. MT4 and PM1
cells were grown in RPMI 1640 medium containing 10%
heat-inactivated FBS (HyClone, Long, UT) supplemented
with 2 mM glutamine (Invitrogen), 2-mercaptoethanol
(50 μM), 100 μg/ml streptomycin (Invitrogen). TZM-bl
cells were cultured in DMEM containing 10% FBS and
100  μg/ml streptomycin. HIV-1NL4-3  was made from
HEK293 after transfection with the proviral DNA fol-
lowed by amplification in MT4 cells.
HIV-1 Infection and Measurements of Viral Production
MT4 or PM1 cells were infected with HIV-1 at a multiplic-
ity of infection (MOI) of 0.001 by low speed centrifuga-
tion (1,200 g) for 1 hr. The use of a relatively low MOI
helped us to identify host factors whose anti-viral effects
may not be robust or directly acting on virus replication
and which will be more likely discovered after multiple
cycles of viral replication. Supernatants collected post
infection were then transferred to the TZM-bl indicator
cell line for determination of infectious viral particles. Rel-
ative Luminescence Unit (RLU) was obtained on TZM-bl
cells after they were treated with Bright-Glo Luciferase
Assay System (Promega) 3 days post infection (dpi).Virology Journal 2009, 6:154 http://www.virologyj.com/content/6/1/154
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Amounts of p24 in the collected supernatants were meas-
ured using HIV-1 p24 ELISA kit (Xpressbio, Thurmont,
MD, USA) following the manufacturer's instructions.
Description of RHGP technology
RHGP utilizes a unique genetic element, known as a gene
search vector (GSV), which is based on a retrovirus or len-
tivirus backbone. The GSV was designed to interrogate the
entire genome and identify targets without any prior
knowledge and that allow host cells to resist or survive
lethal HIV-1 infection.
As demonstrated previously (reference [10]) and modi-
fied in Figure 1, our experimental strategy makes use of
integration of the GSV at a single site in the genome,
where it regulates expression of the target gene via an
inducible promoter. The GSV could integrate in either a
sense or an antisense orientation. In the antisense config-
uration, the integration event itself inactivates one allele
and facilitates expression of an antisense construct, which
further knocks down expression of genes encoded on the
other allele (Figure 1, left panels). In this way, RHGP gen-
erates homozygous perturbation of both gene copies in
diploid cells. When GSV integrates in the sense orienta-
tion, RHGP facilitates over-expression of the target gene
(Figure 1, right panels). This outcome could lead to over-
expression of an entire gene when insertion is upstream of
the start codon or expression of specific domains initiated
from a downstream endogenous start codon when inte-
gration occurs within a gene. This newly truncated protein
could produce a dominant-negative inhibitor. In the case
when the wild type protein has a tendency to form a dimer
or multimer, the mutant partner thus triggers rapid degra-
dation of the complex due to misfolded aggregates they
form into. As such, RHGP allows us to sample the entire
cell genome to identify different types of events that
render host cells to resist or survive HIV-1 infection. The
transcript production is under control of a ligand induci-
ble promoter that carried in the GSV and viral resistance is
derived in the presence of the ligand (promoter "On").
An overview of potential outcomes of GSV integration into the genome Figure 1
An overview of potential outcomes of GSV integration into the genome. The left panels demonstrate how integra-
tion of the Gene Search Vector in an "antisense orientation" would disrupt Allele 1 and then facilitate overexpression of an 
antisense to disrupt the second allele in the presence of inducer (RSL1). On the other hand, the right panels demonstrate how 
integration in a sense orientation would facilitate overexpression of the target gene (or domains thereof). Note that the phe-
notype is tightly regulated by the RSL1-inducible promoter, thus allowing the investigation to reverse the phenotype by turning 
the GSV vector "off" when cells are cultured in the absence of RSL1.Virology Journal 2009, 6:154 http://www.virologyj.com/content/6/1/154
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The causal relationship between the disturbed genotype
and viral resistant phenotype can be confirmed by with-
drawal of the ligand (promoter "Off").
Construction of the MT-4 R1 Cell Lines
RheoSwitch®  Mammalian Inducible Expression System
was purchased from New England Biolabs (NEB). Plas-
mid pNEB-R1 encoding the transactivator R1 was first lin-
earized using the restriction enzyme ScaI (NEB). MT4 cells
were then transfected with the linearized pNEB-R1 by
electroporation using Eppendorf Multiporator (Eppen-
dorf, AG 22331, Hamburg, Germany) under conditions of
360 v (voltage) and 100 μs (time constant). The trans-
fected MT4 cells were selected using G-418 (400 μg/mL)
and G-418 resistant cells were cloned by serial limited
dilutions. After expansion, clones were examined at least
twice for luminescence (relative luminescence units
(RLUs)) after transfection with an R1-responsive luci-
ferase reporter gene (pGluc, NEB) using the Gaussia Luci-
ferase Assay Kit (NEB). We determined the RSL1
induction folds of luminescence from these cell clones as:
RLUs obtained from samples in the presence of the
inducer divided by RLUs from samples without the
inducer treatment. The induction fold from these clones
ranged from 2-60 folds. A stable clone (#2-14) with the
highest induction was chosen to create RHGP libraries.
Construction of the RHGP Gene Search Vector, pRHGP12-
RSN
The RHGP gene search vector, pRHGP12-RSN, was con-
structed using the lentivirus-based pLEST vector as a back-
bone (generously provided by Dr. Stanley Cohen,
Stanford) [16]. This vector was constructed with RheoS-
witch Mammalian Inducible System (NEB) (Figure 2).
The Rheoswitch system contains five copies of the GAL4
response element (5 × RE) upstream of a TATA box that
results in high induction of transcription with low basal
expression in the presence of RSL1 ligand. To construct
the vector, the DNA sequence of NeoR -TRE-CMV in pLEST
was first replaced with a RheoSwitch (RS) inducible
Expression cassette containing Ori-CAT-RS in an orienta-
tion inverted to that of 5'LTR. The selection marker and
reporter cassette containing the Blasticidin (BS) resistant
gene and an EGFP gene controlled by a PGK promoter was
inserted in the NheI site in an orientation opposite to the
RS expression cassette.
Production of Lentivirus Carrying GSV and Construction of 
RHGP Library
RHGP lentiviruses were produced using ViroPower
Expression System (Invitrogen). HEK293FT cells were
plated in 10 cm plates at 106 cells per plate. After 24 h
incubation, the cells were transfected with 3 μg RHGP12-
RSN and 9 μg ViroPower Packaging Mix using Lipofectim-
ine 2000 (Invitrogen). The medium was changed after 5 h
incubation. After 48 h, viruses in the culture medium were
filtrated through a 0.45 μm filter and titrated according to
the manufacturer's instruction.
To construct the RHGP library, MT4-R1 cells were trans-
duced with RHGP viruses in the presence of polybrene (6
μg/mL) by low speed centrifugation (1,200 g) for 1 h. To
minimize the potential for multiple insertions within a
single cell, a low MOI (0.1) was employed during the
library creation to minimize the likelihood that cells
might be transduced by more than one different GSV. GSV
integrated cells were selected using GBL medium (com-
plete RPMI 1640 medium containing G418 (400 ug/ml),
Blasticidin (4 ug/ml) and RSL1 ligand (0.5 uM)).
Selection of RHGP Cell Clones That Survived from HIV-1 
Challenge and Confirmation via Reversibility of Viral 
Resistance
After challenge with HIV-1NL4-3, the MT4-R1 RHGP library
was cultured in the same GBL medium described above.
The individual surviving clones were established by serial
limited dilutions and continuously expanded in GBL
medium. Cell clones were further challenged with HIV-
1NL4-3 to confirm their resistance.
To verify reversibility of RHGP induced events, the viral
resistant MT4 cell clones were cultured in the GBL
medium or GBL medium without RSL1 separately for at
least 3 days before HIV-1 re-challenge. Viral production
(infectivity and p24) in supernatants were examined as
described above.
Identification of Candidate Genes from Virus Resistant 
Clones
The RHGP gene search vector was designed to efficiently
discover target genes and determine the orientation (sense
An overview of the pRHGP12-RSN Gene Search Vector  (GSV) Figure 2
An overview of the pRHGP12-RSN Gene Search Vec-
tor (GSV). Unique and important features of the vector are 
highlighted that facilitate the RHGP-based identification of 
host-based gene targets contributing to HIV-1 resistance. 
Note that the promoter used for production of the GSV 
"Packaging Promoter" is not included into the GSV viral 
genome and the 5' LTR is replaced with the SIN 3'LTR after 
the vector integrates into the cellular genome.Virology Journal 2009, 6:154 http://www.virologyj.com/content/6/1/154
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or antisense) of an integration event. The gene search vec-
tor contains an Ori-CAT reporter gene (Figure 2), which
can be rescued by restriction enzyme-based genomic DNA
cloning as described before[10]. Briefly, cellular genomic
DNA from each cell clone was extracted from 106 cells.
Purified genomic DNA was then digested with BamHI or
XbaI and self-ligated overnight using T4 ligase (Invitro-
gen). The ligated DNA was electroporated into DH10B
ElectroMax competent cells (Invitrogen). After overnight
growth, multiple colonies were isolated for plasmid DNA
preparation and restriction enzyme digestion. The plas-
mid DNA was further used to identify the target genes by
DNA sequencing and genome mapping. The resulting
genomic DNA sequences flanking the RHGP vector inser-
tion sites were subjected to genome mapping against the
human genome using the UCSC Genome Browser http://
www.genome.ucsc.edu/cgi-bin/hgBlat.
Validation of Identified Host Target Genes with siRNA 
Knockdown Assay
Human duplex siRNA (siGNOME SMARTpool) for RHGP
identified genes were prepared as recommended by the
manufacturer (Dharmacon). The siRNA Rab6A and HIV-1
Tat were employed as positive controls [17]. Non-target-
ing siRNA (siCONTROL1) was used as a negative control.
MT4 or PM1 cells were cultured in fresh complete RPMI
1640 medium overnight. The log-phase growing cells
were transfected with 1.2 uM of siRNA by electroporation,
according to the manufacturer's instruction (Eppendorf).
The voltage and time constant for elctroporation were 360
v, 100 μs and 200 v, 200 μs for MT4 and PM1 cells, respec-
tively. The cells were infected with HIV-1 variants 24 h
post transfection. Culture media were refreshed everyday
and the cell viabilities were examined daily by trypan blue
dye exclusion assay. Viral production (infectivity and p24)
in supernatants were examined as described above.
Western Blot Analysis
The cell pellets were washed with PBS, resuspended with
lysis buffer (25 mM Tris-HCl, pH 7.6, 150 mM Nacl. 1%
NP-40. 1% Sodium Deoxycholate, 0.1% SDS), and dis-
rupted with pulse sonication. After centrifuge at ≅14000 ×
g for 15 minutes, the supernatant was dialyzed against
PBS, and concentrated. Equal amounts of protein samples
(250 μg) were loaded onto 4%-12% stacking SDS-PAGE
with Dithiothreitol (DTT, 200 mM) before electrophore-
sis analysis. The sieved proteins were transferred on to
PVDF membranes, blocked with PBS containing 5% dry
non-fat milk, and blotted with 1:50 dilution of anti-
Robo1 (A301-265A, Bethyl Laboratories) as primary anti-
body and 1: 2000 as secondary antibody HRP in PBS con-
taining 5% dry non-fat milk, 0.1% Tween-20 and the ECL
Chemiluminescence (Amersham/Pharmacia Biotech) was
used to detect signals. The loading amounts controls were
probed using anti-HSP (heat shock protein 90) (abcam,
Cambridge, MA) and anti-GAPDH (Santa Cruz Biotech-
nology, Santa Cruz, CA).
Results
Construction of the RHGP library of CD4+ T cell line MT4
To identify novel targets that render T cells resistant to HIV
infection, we utilized the human MT4 cell model, which
provided an HIV-1 permissive, CD4 positive T lym-
phocyte cell line. The use of a natural target line for a wild-
type strain of HIV-1 provided a model to identify targets
that are physiologically relevant to the HIV life cycle. In
addition, MT4 cells were selected for these studies, in part,
after confirming that this model was highly sensitive to
HIV-1 infection. Specifically, challenge of MT4 cells with
HIVNL4-3, at a relatively low initial MOI (0.001), was suffi-
cient to eliminate MT4 cells in the absence of RHGP-
mediated gene perturbation.
A key feature of the RHGP technology is the ability to val-
idate candidate targets via regulation by an inducible pro-
moter 5xRE (Figure 2). MT4 T cells were first engineered
to stably express a transactivator (known as R1), which
can activate the built in promoter 5XRE in RHGP to pro-
duce transcripts in the presence of the inducer RSL1 (Fig-
ure 3, step 1). MT4-R1 cells were thus transfected with an
R1-responsive luciferase reporter gene and cultured in the
presence or absence of the inducer RSL1. Luminescence
readings (RLUs) demonstrated that the resulting MT4-R1
cells generated high and stable levels of luminescence, but
only in the presence RSL1 (Figure 4). This result indicated
that the activation ability of R1 on the promoter 5xRE is
tightly controlled by RSL1. Similar to its parental MT4
cells, we confirmed that these cells retained their suscepti-
bility to HIV-1 infection as complete cell loss was
observed after infection of HIV-1NL4-3.
We then utilized RHGP to interrogate the genome of
human T lymphocytes to identify targets that allow these
cells to survive an otherwise lethal infection with HIV-1.
To accomplish this, cultures of MT4-R1 cells were trans-
duced with the GSV (pRHGP12; Figure 2), which contains
an expression cassette consisting of a constitutive pro-
moter driving a Blasticidin resistance gene. Blasticidin
selection allowed us to establish an "RHGP library" of
MT4-R1 cells with different genetic perturbations ren-
dered by random GSV integrations (Figure 3, step 2). To
maintain stable R1 expression and GSV integration, the
MT4-R1 RHGP library was continuously incubated with
G418 and Blasticidin. RSL1 was also included in the cul-
ture medium to ensure that the activated GSV promoter
was able to generate anticipated RHGP effects by produc-
ing transcripts. To control for the quality of the library, we
confirmed that downstream gene expression from the
GSV was induced only upon incubation with RSL1 but
not when RSL1 was absent (data not shown). StatisticalVirology Journal 2009, 6:154 http://www.virologyj.com/content/6/1/154
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analyses of gene expression and genome size were imple-
mented to ensure that a sufficient number of GSV integra-
tion events would be analyzed to thoroughly evaluate the
human genome, both for gain or loss of target expression.
Specifically, we calculated that a library of MT4-R1 cells
with 105 GSV integration events would ensure coverage of
the human genome[18].
Isolation of cell clones resistant to HIV-1 infection
The cell library containing the different RHGP perturba-
tion MT4 cells was then challenged with HIVNL4-3, infected
at an initial MOI of 0.001 (Figure 3, step 3). Analysis of
Trypan blue exclusion examination indicated that non-
transduced MT4-R1 cells were greater than 99% depleted
following HIV-1NL4-3 challenge. As indicated above, we
also confirmed that the inclusion of RSL1 in non-trans-
duced cells did not alter cell sensitivity to HIV-1 infection.
As an additional control, parallel cultures of mock-trans-
duced cells were treated identically and no survivors were
observed after 5 days. These controls confirmed that sur-
viving cells arose as a result of the RHGP perturbation and
not as an artifact of spontaneous resistance to HIV-1. The
small number of surviving cells was cloned and expanded.
The resulting clones were then subjected to multiple
rounds of challenge to eliminate any susceptible cells.
Ultimately, we obtained 25 different cell clones that were
insensitive to the lethal HIV-1 challenge.
Although our results indicated that the RHGP technology
prevented HIV-mediated killing of infected cells, we could
not exclude that these cells were able to stay alive and yet
propagate virus (a less desirable phenotype). We thus
asked if the resistant cell clones carrying GSV continued to
produce viral particles upon HIV infection. After re-chal-
lenge of these resistant cell clones with HIV-1NL4-3 in the
presence of RSL1, the supernatants were collected at 4
days post infection (dpi) and were transferred to the TZM-
bl cells, which provided readout of infectivity. Notably,
the RHGP cell clones failed to produce and release prog-
eny virus (See Figure 5 for a representative finding). In
contrast, HIV-1 established a productive infection in non-
transduced MT4-R1 cells and was ultimately cytotoxic. We
confirmed these findings by independently demonstra-
tion of diminished p24 levels in the supernatants of
RHGP-perturbed clones (data not shown). Thus, we were
able to confirm that the RHGP-mediated resistance to HIV
killing related directly to elimination of virus propaga-
tion.
As another means to eliminate potential artifacts, we
exploited the reversible nature of the RHGP technology.
To eliminate clones that might have survived viral infec-
tion as a result of events unrelated to RHGP, HIV propa-
Schematic overview of the experimental strategy to identify  host genes involved in HIV-1 infection using RHGP Figure 3
Schematic overview of the experimental strategy to 
identify host genes involved in HIV-1 infection using 
RHGP. MT4 cell lines expressing the transactivator R1 were 
first constructed. Following transduction with the RHGP vec-
tor antibiotic selection was used to establish an "RHGP 
library" of gene perturbations. Next the RHGP library cells 
were challenged with a lethal infection of HIV-1 virus in the 
presence of the inducer RSL1. Survivors were cloned and 
then validated by reversing the RHGP phenotype in the 
absence of RSL1. The genomic DNA was then isolated from 
those validated clones and the identity of the target gene, 
along with the orientation of the GSV integration event 
("Sense" or "Antisense") was then determined.
Activation of a luciferase reporter gene by inducer RSL1 in  the MT4-R1 cell line expressing RheoSwitch R1 Figure 4
Activation of a luciferase reporter gene by inducer 
RSL1 in the MT4-R1 cell line expressing RheoSwitch 
R1. Cells were transfected with plasmid DNA encoding a 
luciferase gene (Luc) or a control plasmid DNA (Ctrl) in the 
presence or absence of the inducer RSL1. Luminescence was 
measured 48 h after transfection.
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gation was compared in the presence or absence of ligand
RSL1 during HIV-1 re-challenge. Each of the RHGP-trans-
duced clones demonstrated reversible resistance to HIV-1
infection (see a representative cell clone in Figure 6A). In
the absence of exogenous ligand, we observed robust viral
production that was comparable to parental controls.
To preclude that the act of the GSV integration into the
MT4 genome might itself impart a nonspecific impact on
HIV-1 replication, we tested naïve MT4 RHGP clones that
had never previously been challenged with HIV-1. As a
representative example, Clone H6 (in which the GSV inte-
grates into the human SC6A3 gene) demonstrated no
resistance to HIV-1, producing levels of HIV-1 production
comparable to parental MT4 cells (Figure 6B). Likewise,
HIV-1 infected H6 cells were completely depleted after
infection (data not shown), thus confirming the specifi-
city of the HIV-resistance demonstrated by the RHGP
strategy.
Identification of the host gene by genomic DNA cloning
To identify the targets perturbed by RHGP in the HIV-
resistant MT4 cells, genomic DNA was isolated from the
clones that demonstrated reversible resistance to HIV-1
(Figure 3, step 4). The 25 HIV-insensitive host cell clones
with GSV integration sites yielded the identification of 21
cellular integration events (Figure 7). These GSV integra-
tions targeted 12 previously-annotated genes and 2 non-
annotated ESTs. Some clones were deemed progeny from
a common parent since the GSV had integrated in the
same genetic location with the same orientation. Three
clones had RHGP insertions in a region without genes or
ESTs. We were unable to isolate candidate genes from 4
cell clones due to partial loss of the Ori-CAT reporter.
The properties of these genes and ESTs are listed in Table
1. The site and orientation of integration offered by RHGP
provided insight into the types of perturbations that
allowed host cells to survive challenge with HIV-1. Specif-
ically, the RHGP perturbations could be broadly divided
Loss of viral production from HIV-1 resistant cell clones  upon HIV-1 re-challenge Figure 5
Loss of viral production from HIV-1 resistant cell 
clones upon HIV-1 re-challenge. Production of progeny 
virus from a representative resistant clone after re-challenge 
by HIV-1NL4-3. Supernatants collected daily starting 3 dpi 
from the cell cultures were then examined for viral amounts 
using TZM-bl cells.
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Validation of cell clones resistant to HIV-1 infection with the reversibility assay Figure 6
Validation of cell clones resistant to HIV-1 infection with the reversibility assay. HIV-resistant RHGP Clone 1-13(A) 
and a naive RHGP Clone H6 (B) were challenged with HIV-1NL4-3 in the presence (RHGP "on") or absence (RHGP "off") of the 
ligand RSL1. Supernatants collected daily starting 3 dpi from these cell cultures were then examined for infectivity using TZM-
bl cells and the results from 5 dpi are shown.
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into three groups: 1) "Antisense": Antisense integration
events that facilitated gene expression disruption of one
allele and antisense inhibition of gene expression from
the other allele; 2) "Sense Downstream": Integration in a
sense orientation, which would be predicted to facilitate
production of a dominant-negative inhibitor of the
endogenous gene product; and 3) "Sense-Upstream":
Integration in a sense orientation upstream of the transla-
tion start site, which would be predicted to facilitate over-
expression of the target gene. Of the 14 gene targets iden-
tified using RHGP, 8 targets represented "Antisense"
knockdown of target expression. The other 6 of the targets
represented "Sense-Downstream" events, likely represent-
ing over-expression of dominant-negative inhibitors of
wild-type gene expression. No "Sense-Upstream" inser-
tions were identified in the current study (Figure 7 and
Table 1). Based on these predictions, all of the candidate
genes are likely down-regulated by a GSV integration
event. This allowed us to directly use siRNA knock down
approach on naïve MT4 cells to recapitulate viral resistant
phenotypes. Altogether, these findings suggest that
RHGP-based interrogation of the host genome had iden-
tified both novel targets and/or ascribed novel functions
to known genes.
Validation of target genes using naïve cells
The studies above demonstrated that RHGP could identify
novel host targets that conferred resistance to HIV-1 infec-
tion. We then sought to verify these candidates using an
independent experimental system to exclude outcomes
that might arise as spontaneous mutation or unantici-
pated artifacts of the RHGP technology. Thus, duplex siR-
NAs targeting these candidates were obtained. Each siRNA
preparation contained a pool of 4 individual siRNAs, all
of which selectively target the gene of interest. Non-target-
ing siRNAs provided a matched control for the transfec-
tion and a reference standard. siRNA constructs specific
for viral Tat and a cellular target, Rab6A, provided positive
controls based on recent reports that these siRNA were
able to efficiently inhibit HIV-1 infection [17].
The siRNAs were transfected into naïve MT4 cells via elec-
troporation one day prior to challenge with HIV-1NL4-3.
Culture supernatants were harvested two days after infec-
tion and the number of infectious virions was measured
using TZM-bl cell-based readouts. As indicated in Figure
8A, duplex siRNAs against the 12 target genes reduced
HIV-1 virus production by 50-90%, which was compara-
ble to the inhibition observed in the positive controls (Tat
and Rab6A). As a control, we also evaluated the overall
viability of the MT4 host cells, which allowed us to
exclude cytotoxic effects that have arisen from siRNA treat-
ment and thus decreased viral release as a result of a gen-
eral decrease in cell viability (rather than a specific impact
on the viral life cycle). Despite the inhibition of HIV-1
release, the viability of siRNA-treated samples was compa-
rable in all samples. These results confirmed that these
genes identified by RHGP are important in viral replica-
tion and validated the application of RHGP to identify
novel host-based targets.
An important goal of our present studies was to identify
targets that are broadly applicable to HIV-1 infection. We
also sought to confirm that targets identified using RHGP
would not be unique to any particular cell system. To
address both issues, we asked if the host gene candidates
that rendered MT4 cells insensitive to challenge by HIV-
1NL4-3 (a CXCR4-tropic virus) would similarly allow a dif-
ferent cell system to become insensitive to challenge by a
CCR5 tropic HIV-1 virus. For this, the same siRNA
approach as used with MT4 cells was used to target relative
molecules in PM1 T cells. PM1 was selected since it
expresses both CXCR4 and CCR5 co-receptors and thus
can provide a model for both R5 and X4-tropic viruses
[11]. Similar to our findings with CXCR4-tropic viruses,
targeting in PM1 cells demonstrated that this same set of
12 siRNAs was able to inhibit viral replication of the R5-
tropic HIV-1ME1[14]. Viral production of HIV-1ME1 strain
was significantly inhibited in the cells treated with specific
siRNA targeting each of these 12 gene targets (Figure 8B).
These results confirmed our findings that the targets iden-
tified using RHGP are important for the replication of
both X4 and R5 tropic HIV-1 viruses.
In the course of validating targets identified using RHGP,
we identified novel mechanistic information about cer-
tain target functions. For example, in clone #1-13, the
integration of the GSV occurred in a "sense downstream"
after start codon of the human Robo1 gene. This integra-
tion was predicted to result in the production of a trun-
cated form of Robo1 (table 1). Western blot analysis with
Robo1 specific antibodies indicated that expression of
An overview of HIV-1 resistant RHGP cell clones and subse- quent discovery of integration locations Figure 7
An overview of HIV-1 resistant RHGP cell clones and 
subsequent discovery of integration locations. Num-
bers of different integration occurrences are indicated blow 
each event.
Resistant cells
25
RHGP Integration 
identified
21
RHGP Integration not identified 
4
Genes identified
12
Unknown ESTs
2
A region without genes or ESTs
3
Perturbation Types 
Antisense
8
Sense downstream
6
Sense upstream
0Virology Journal 2009, 6:154 http://www.virologyj.com/content/6/1/154
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Table 1: Summary of properties of identified HIV-1 resistant cellular genes
Target genes Main known function Cellular localization C'# Perturbation siRNA validation
CASD1 CAS1 domain-containing 
protein 1 precursor
O-acetyl-transferase Multi-pass membrane 
protein
7A n t i s e n s e  i n t r o n  4  
Down-regulation
Yes
HECW2 HECT, C2 and WW 
domain-containing protein 2
NEDD4-like E3 ubiquitin-protein ligase 2 Intracellular 2 Sense intron15 ATG(sc) exon 
7 Down-regulation (DN)
Yes
ROBO1 roundabout protein 
homolog 1
axon guidance receptor and cell 
adhesion receptor
Type I membrane protein 3 Sense intron 3 ATG(sc) exon 
3 Down-regulation (DN)
Yes
NLGN1 member of the 
neuroligin family
splice site-specific ligands for 
beta-neurexins and may be involved in 
the formation and remodeling of central 
nervous system synapses
Neuronal cell surface 3 Antisense intron 3 
Down-regulation
Yes
DZIP3 
(DAZ-interacting protein 3)
E3 Ubiquitin ligase proteins. Specifically 
bind RNA. Also called huRUL138 
(RNA-binding ubiquitin ligase of 138 
kDa)
Intracellular 3 Antisense intron 1 
Down-regulation
Yes
CAMSAP1L1 calmodulin 
regulated spectrin-associated 
protein
may be involved in spectrin's function as 
a cytoskeletal protein providing a 
scaffolding and maintenance of plasma 
membrane
Membrane 1 Antisense intron 2 
Down-regulation
Yes
GSTCD glutathione S-transferase 
(GST), C-terminal domain
structural domain of GST, which 
conjugates reduced glutathione to a 
variety of targets to facilitate 
detoxification of the targets
Intracellular 4 Antisense intron 5 Down-
regulation
Yes
CPSF1 Cleavage and 
polyadenylation specificity factor
It recognizes the AAUAAA signal in the 
pre-mRNA and facilitates both RNA 
cleavage and polyA synthesis
Nucleus 8 Antisense intron 2 
Down-regulation
Yes
GDAP2 ganglioside 
induced differentiation associated 
protein 2
a signal transduction pathway during 
neuronal development
Intracellular 1 Sense last exon 
Down-regulation (DN)
Yes
TNRC6A trinucleotide repeat 
containing 6 protein
post-transcriptional gene silencing 
through the RNAi and microRNA 
pathways.
Cytoplasmic bodies 16 Sense intron 4 ATG(sc) exon 
1 Down-regulation (DN)
Yes
TTC21B tetratricopeptide repeat 
domain 21B
may negatively modulate SHH (Sonic 
Hedgehog) signal transduction and may 
play a role in retrograde intraflagellar 
transport in cilia
Intracellular 2 Antisense intron 4 Down-
regulation
Yes
ATP8A1 aminophospholipid 
transporter (APLT), Class I, type 
8A, member 1
transport of aminophospholipids from 
the outer to the inner leaflet of various 
membranes and the maintenance of 
asymmetric distribution of 
phospholipids, mainly in secretory 
vesicles
Membrane 4 Sense intron 4 ATG(sc) exon 
1 Down-regulation (DN)
Yes
Unknown ESTs BE066906, AW817767, EB388641 unknown 3 Sense n.d.
AW300614 unknown 2 Antisense n.d.
Symbols, gene families and the currently main known functions are shown for each identified gene. C# indicates the chromosome number of each 
target gene locates. The disruption effects upon GSV integration (orientation and integrated sites in host genes) are also listed. In order to determine 
the possible effects of sense integration on host gene expression, locations of the translation start codon (ATG(sc)) are also indicated. Down-
regulation of gene expression is expected for the targeted genes through anti-sense inhibition. Dominant Negative (DN) effects are also anticipated 
from the targeted genes with over-expression of a truncated host protein when GSV inserts downstream of the start codon ATG in the sense 
orientation. GenBank Access numbers and the disruption effects of GSV integration are also shown for the two unknown ESTs. "n.d." stands for "not 
done".Virology Journal 2009, 6:154 http://www.virologyj.com/content/6/1/154
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wild type Robo1 (~220 kDa) in clone #1-13 was down
regulated after GSV integration (Figure 9A). Other immu-
noglobulin superfamily members require multimeriza-
tion [19,20] and improperly folded multimers are likely
to be efficiently degraded. Thus, we reasoned that the
truncated molecule might favor degradation of endog-
enous Robo1. When the RHGP promoter turned "off"
upon withdrawal of ligand RSL1, the truncated protein
was no longer produced and normal levels of Robo1
expression reemerged (Figure 9A). Likewise, viral replica-
tion increased upon removal of RSL1 (Figure 6A), which
directly related to the restoration of wild-type Robo1 pro-
tein.
To validate the targets identified using RHGP, we sought
to reproduce the perturbation in a "naïve" cell that has not
been modified by the GSV. To verify that the siRNA target-
ing Robo1 in naïve T cells significantly reduced viral pro-
duction during HIV-1 infection (Figure 8), we next
examined whether Robo1 expression was successfully
knocked down upon siRNA treatment using western blot.
Indeed, reduced amounts of Robo1 were found in the
siRNA treated cells (Figure 9B).
Resistance of RHGP cell clones to drug-resistant HIV-1
Although the results with wild-type HIV-1 were encourag-
ing, we considered that a large unmet need for therapeu-
tics is the application of new targets to viral variants that
are resistant to conventional medicines. Therefore, we per-
formed studies with an HIV-1 variant (L10R/M46I/L63P/
V82T/I84V) with established resistance to protease inhib-
itors[15]. The RHGP-transduced clones selected after wild
type HIV-1NL4-3 challenge also survived challenge in the
face of the protease-resistant variant and failed to produce
viruses after challenge. This outcome was not unique to
host cell survival as infectivity assays as well as p24 ELISA
confirmed the defective infection by mutant HIV-1 in the
resistant cells (Figure 10 and data not shown). Together
these results confirmed the cell clones we obtained are
resistant to infection by both wild type and drug resistant
HIV-1 variants and further indicated that therapeutics
based on the identified gene targets have the broad spec-
trum potential against replication of HIV mutants resist-
ant to current anti-viral drugs.
Discussion
In our present study, we applied RHGP technology to con-
duct a genome-wide screen for host factors required for
HIV-1 virus infection and identified novel host-based tar-
gets that render cells resistant to an otherwise lethal chal-
lenge with HIV-1 virus. In addition, we ascribed novel
anti-HIV-1 functions to previously-known genes as well as
non-annotated ESTs. These targets were validated first
using an inducible promoter incorporated within the
RHGP vector to reverse the phenotype and then in naïve
cells using the conventional siRNA approach. We further
found that the resultant targets were broadly applicable to
different HIV variants, including CCR5 and CXCR4-tropic
viruses. We further showed that cell clones with the gene
targets disrupted by RHGP were resistant to viral challenge
by a drug resistant HIV-1 mutant.
An independent study from our group recently identified
host targets that allow host cells to survive in the face of
an otherwise lethal infection with influenza virus[10].
That study, as well as the work herein, employed a lentivi-
ral system to overcome the prior limitation of low GSV
production, which had been a problem associated with
Moloney murine leukemia virus (MMLV)-based strategies
[9]. These improvements allowed us to sample the entire
host genome and identify 12 gene targets from the 10^5
integration events invoked by the improved GSV. Consist-
ent with prediction that a lentiviral vector favors single
site insertion into sites of active gene transcription [21],
all integration occurred in regions with active gene expres-
sion.
Based on MMLV-derived vectors which randomly inte-
grate into the host chromosome, insertional mutagenesis
was described as a high-throughput forward genetics
approach to inactivate and thus discover cellular genes.
Using these vectors cellular genes were identified that are
required for replication of HIV-1 and other viruses, but
not for host cell survival [22,23]. With a built-in inducible
promoter in GSV to drive transcript production from a
host gene, our RHGP can also generate activation, often
over-expression, of genes in mammalian cells, depending
on the location and direction of GSV insertion relative to
the candidate gene. Although not observed in our current
study, over-expression of a subset of targets including the
B-cell CLL/lymphoma 2 (BCL2) allowed MDCK cells to
survive influenza infection during discovery of host genes
against influenza virus infection[10]. Since target expres-
sion is under control of the inducible promoter, the causal
relationship between the phenotype (resistance to HIV-1
infection) and the perturbed gene can be confirmed by
withdrawal of the inducer. By validating these targets
within the same experiment, this feature markedly
increases the efficiency of discovery of therapeutic candi-
dates. Indeed, all the targets from resistant clones were
successfully confirmed in the subsequent siRNA studies
with naïve cells. Instead of transient knock down effects
generated by conventional approaches (e.g., siRNA), the
RHGP phenotype is highly stable, which can allow mech-
anistic studies to continuously characterize the roles of
these perturbed genes in HIV-1 replication.
Increasing evidence suggests that the concept of host-ori-
ented therapeutics may be particularly useful for identify-
ing improved opportunities to combat HIV/AIDS. ToVirology Journal 2009, 6:154 http://www.virologyj.com/content/6/1/154
Page 11 of 14
(page number not for citation purposes)
Validation of candidate genes providing HIV-1 resistance via siRNA targeting of naïve T lymphocytes Figure 8
Validation of candidate genes providing HIV-1 resistance via siRNA targeting of naïve T lymphocytes. Naïve T 
cells were challenged one day after electroporation with the siRNAs specific for the human targets listed in Table 1. Produc-
tion of the progeny virus 48 h post-infection were quantified using TZM-bl cells. Percentages of virus production from each 
siRNA treatment against the non-targeting siRNA control sample are shown. Note that siRNA against Tat and Rab6A provided 
positive controls for established HIV-1 siRNA targets. (A) Data from siRNA transfected MT4 cells followed by X4 tropic HIV-
1NL4-3 infection. Percentages of viable cells after siRNA transfection and viral infection (2 dpi) are shown in the bottom. (B) 
Results from siRNA transfected PM1 cells followed by infection with the R5 tropic HIV-1Mei virus.
A
B
MT4 cells challenged with X4 virus
PM1 cells challenged with R5 virus
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identify relevant host targets, recent siRNA or shRNA
based genome-wide studies have successfully identified
host targets associated with HIV-1 infection [17,24-26].
Unfortunately, siRNA is intrinsically limited by the need
for strong and stable over-expression of the siRNA. More-
over, the outcomes of some siRNA findings have been
clouded by recent questions of whether the siRNAs might
non-specifically alter host defense mechanisms [27],
which could be particularly problematic for applications
of siRNA technology to therapies against viral diseases.
Any siRNA screen is likely to generate false positive and
false negative data due to the potential "off-target effects"
along with variability both in siRNA efficacy and protein
half-lives. This variability will ultimately lead to different
levels of protein knockdown. We believe RHGP could
provide an alternative since it is not limited by these same
constraints.
Notably, the genes indentified herein are not included in
the list discovered by the three recent siRNA-based HIV-1
studies [17,24,25]. We postulate this discrepancy may
reflect that the different cell systems, viruses and
approaches were used during screening coupled with con-
trasting experimental designs. Consistent with this postu-
lation, there was very limited overlap between the HIV
dependency factors identified in these investigations[28].
These earlier studies did not utilize CD4+ T lymphocytes,
a natural cell target for HIV infection. To achieve efficient
siRNA delivery and investigate viral replication in those
studies, adherent HeLa -derived cells were reconstructed
to express CD4 and CXCR4 (such as TZM-bl cells used in
the Brass et al screen [17] or P4/R5 cells in the Zhou et al
study [25]). In a third investigation, a mutant HIV-1 virus
pseudotyped with VSV-G was used to allow virus entry
[24]. This raises a question as to whether such differences
might alter the mechanism of viral replication. Consistent
with this, defective viral budding was observed in TZM-bl
cells (our unpublished data). Using CD4+ T lymphocytes
and wild type HIV-1 virus, we were able to interrogate very
natural interactions between the entire repertoire of host
factors and viral proteins during complete cycles of viral
replication. We also noted that while we sampled the
whole genome, a relatively low number of host genes
(<20) were identified in our study. This subset of candi-
dates might have resulted from the fact that our strategy of
cloning surviving cells might have precluded targets that
impact cell growth rates or viability. Likewise, the use of
cell models and laboratory adapted viruses might have
limited or biased the repertoire of host targets identified
using RHGP. Thus, future studies should seek to adapt this
technology using virus isolates obtained from primary
cells.
Confirmation of target gene expression using Robo1 as an  example Figure 9
Confirmation of target gene expression using Robo1 
as an example. (A). Loss of Robo1 expression in the 
RHGP clone whose robo1 gene was perturbed by RHGP in 
the presence of RSL1 (on) and reemergence of expression in 
the absence of RSL1 (off). Cell lysates of WT MT4 cells and 
RHGP clone were resolved in an SDS-PAGE gel. After trans-
fer to a membrane, the blot was first probed by anti-Robo1 
(A301-265A, Bethyl Laboratories) and then anti-HSP90 (heat 
shock protein) after stripping, each followed by 2nd HRP-con-
jugated anti-rabbit Ab. (B). Knockdown expression of Robo1 
in MT4 cells treated with siRNA against robo1. Cell lysates 
from samples treated with different siRNA as indicated were 
processed into western blot as described above. Herein 
GAPDH protein probed by an anti-GAPDH was used as a 
loading control.
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Failure to produce virus by the HIV-1 resistant RHGP cell  clones upon challenge by a protease inhibitor resistant HIV-1  mutant Figure 10
Failure to produce virus by the HIV-1 resistant 
RHGP cell clones upon challenge by a protease inhib-
itor resistant HIV-1 mutant. Production of progeny virus 
were examined on supernatants by TZM-bl cells after cells 
from parental MT4-R1 and resistant cell clones were chal-
lenged with the protease inhibitor resistant HIV-1 mutant 
(L10R/M46I/L63P/V82T/I84V). Results from 4 dpi are shown.
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
 
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
!
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
"
￿
￿
#
$
%
&
’
(
)
*
)
(
+

,
-
.
/
0Virology Journal 2009, 6:154 http://www.virologyj.com/content/6/1/154
Page 13 of 14
(page number not for citation purposes)
A central tenet of the RHGP technology is that it is not
biased by prior knowledge of the target. Consistent with
this, two (of 14) that render host cells resistant to HIV
infection were ESTs that had not yet been annotated
(Table 1). Analysis of target function via the PANTHER
Classification System [29], indicated little (CASD1,
GDAP2, TNRC6A, and TTC21B,) or no (CAMSAP1L1 and
GSTCD) knowledge of target function. The function for
four targets have been ascribed (ROBO1, NLGN1, CPSF1,
ATP8A1), but none of them have been linked with viral
infection. The biological processes that these targets are
involved in diversely include mRNA polyadenylation
(CPSF1), cation transport (ATP8A1) and cell adhesion
mediated signaling (ROBO1 and NLGN1).
HECW2 and DZIP3 are members of the E3 ubiquitin
ligase family. This finding is intriguing since the ubiquitin
ligase pathway has been shown to be necessary for the
budding and release of HIV-1 and other viruses. For exam-
ple, the TSG101 host protein is a ubiquitin-like ligase that
interacts with HIV-1-encoded p6 Gag and is "hijacked" to
facilitate viral egress from the cell surface [6]. Likewise,
Nedd4 is another ubiquitin ligase that regulates viral bud-
ding and release including HIV-1 [30,31]. It is notable
that HECW2 shares considerable homology with Nedd4
[32]. It is thus tempting to postulate that HECW2 and
DZIP3 may be also important for HIV-1 maturation and
egress.
Robo1 is also essential for HIV replication. Viral produc-
tion was markedly inhibited in both RHGP promoter
"on" cells and siRNA treated naïve cells where knockdown
of Robo1 expression were observed (Figure 8 and 9). This
consistency was demonstrated again in RHGP cells in the
subsequent reversibility assay when inducible promoter
turned off and where levels of viral replication increased
with the reemergence of Robo1 expression (Figure 9A).
Robo1 is a type I transmembrane protein with an extracel-
lular N-terminus comprising of 5 immunoglobulin and 3
fibronectin domains [20]. It was originally identified as
axon guidance receptor during neuronal development
and was recently shown to regulate T cell chemotaxis
[33,34].
Our work thereby provides potential insights into new
opportunities for host-directed therapeutics. Specifically,
novel technologies like RHGP provide an opportunity to
identify and prioritize host molecules that might provide
safe and effective targets for drug intervention. In light of
the increasing evidence that different virus types can share
essential host pathways during their replication cycles, the
therapeutics developed from genes identified in this study
might also have broad application to other viruses as well.
Conclusion
Using RHGP, we have successfully identified novel host
cell targets that are essential for HIV-1 replication but
which can be safely targeted to preclude damage to nor-
mal cells. These targets emphasize safety while effectively
blocking viral propagation. Most current HIV drugs target
the HIV virus and therefore are vulnerable to the develop-
ment of drug resistance through viral mutation. In con-
trast, therapeutics based on these newly identified human
host targets will prevent HIV virus from using the host's
cellular mechanism for its life cycle and are insensitive to
drug resistance. Moreover, by targeting cellular pathways
shared by HIV variants and even viruses other than HIV,
these therapies have potentially broad spectrum anti-viral
activities.
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